Suzuken : Notice Regarding Acquisition of Treasury Shares by Own Share Repurchase Trading (ToSTNeT-3)
November 13, 2023
Share
November 14, 2023
Press Release SUZUKEN CO., LTD.
Shigeru Asano, President and CEO (Stock Code: 9987)
Securities Traded: Prime Markets of the Tokyo and Nagoya Stock Exchanges, and the Sapporo Securities Exchange
Contact: Yuichi Yamamoto, Executive Officer, Senior General Manager of Corporate Group Planning Headquarters
Tel.: +81-52-961-2331
Notice Regarding Acquisition of Treasury Shares by Own Share Repurchase Trading
(ToSTNeT-3)
(Acquisition of treasury shares in accordance with the Articles of Incorporation pursuant to the provision of
Article 459, Paragraph 1 of the Companies Act)
Suzuken Co., Ltd. (hereinafter, "the Company") hereby announces that it has decided the specific method and details for the acquisition of treasury shares which were resolved by the Board of Directors on November 10, 2023
in accordance with the Articles of Incorporation pursuant to the provision of Article 459, Paragraph 1 of the Companies Act. Details are as follows:
1. Acquisition Method
The Company will place an order to purchase shares at 8:45 a.m. on November 15, 2023, through the own share
repurchase trading (ToSTNeT-3) of Tokyo Stock Exchange, Inc. The acquisition price will be the closing price of the Company's shares today (November 14, 2023), ¥4,861. (This will not be changed to another transaction system or time). The buy-order will be placed only at this time.
2. Acquisition Details
(1) Type of shares to be acquired
Common shares
(2) Total number of shares to be acquired
2, 800, 000 shares (upper limit)
(3) Total acquisition value of shares
¥13, 610.8 million (upper limit)
(4) Announcement of acquisition result
The acquisition result will be announced after
the transaction is complete at 8:45 a.m.
(Notes)
The number of shares to be acquired will not be changed. However, it is possible that some or all of the shares will not be acquired due to market fluctuations, etc.
The repurchase will be conducted based on buy-orders corresponding to the planned number of shares to be acquired.
On or after the day following the acquisition date (November 15, 2023), the Company plans to continue acquisition of treasury shares through market purchase including Tokyo Stock Exchange Trading Network Off- Auction Own Share Repurchase Trading System (ToSTNeT-3), up to the quantity and amount obtained by deducting the total number of shares and acquisition value using the above method from the total number of shares and acquisition value to be acquired as resolved at the Board of Directors stated below.
(Reference) Details of Resolution to Acquire Treasury Shares (Announced on November 10, 2023)
(1) Type of shares to be acquired
Common shares
(2) Total number of shares to be acquired
6,000,000 shares (upper limit)
(% to total number of shares outstanding
(excluding treasury shares): 7.24%)
(3) Total acquisition value of shares
¥25 billion (upper limit)
(4) Acquisition period
November 13, 2023 to March 8, 2024
(5) Acquisition method
Market purchase including Tokyo Stock
Exchange Trading Network Off-Auction Own
Share Repurchase Trading System (ToSTNeT-
3)
This is an English translation of a statement written initially in Japanese and is provided for reference purposes only. The Japanese original shall prevail in the event of any discrepancy between this document and the original.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Suzuken Co. Ltd. published this content on 14 November 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 November 2023 01:57:06 UTC.
Suzuken Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The Company operates in four business segments. The Pharmaceutical Wholesale segment sells pharmaceuticals, diagnostic drugs, and medical equipment and materials, among others. The Pharmaceutical Manufacturing segment manufactures pharmaceuticals and diagnostic drugs and others. The Insurance Pharmacy segment is engaged in dispensing operations based on prescriptions from medical institutions. The Medical-related Service and Others segment is engaged in the provision of manufacturer support services, such as the transportation of medicines and comprehensive support for the distribution of drugs for rare diseases; the nursing services; the manufacture of physiological examination equipment, such as electrocardiographic monitors and blood pressure monitors; as well as other services, such as the sale of medical books.